Clinical Trial Update: A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone [Phase 4]

View source ↗

Summary

Phase IV study evaluating Rebif (interferon beta-1a) 44 mcg given subcutaneously three times weekly versus no treatment after mitoxantrone in relapsing-remittin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Rebif (interferon beta-1a)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Status: COMPLETED | Results posted: 2011-06-10